Challenging AD expectations: A new therapy option that challenges treatment goals for patients with refractory, moderate to severe atopic dermatitis (AD) who are not adequately controlled with other systemic drug products

Friday, March 25


Aad Inc Abbvie Logo

Please join Dr. Peter Lio for an evening educational program. The goals of this program are to understand the burden of AD, to discuss the efficacy and safety of RINVOQ in patients with moderate to severe atopic dermatitis and to review resources available through RINVOQ Complete.

When: Friday, March 25 | 6:30 p.m. Registration | 7:15 p.m. Dinner and Program

Where: Momentum D | Omni Boston Hotel at the Seaport